DE60105025D1 - Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie - Google Patents

Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie

Info

Publication number
DE60105025D1
DE60105025D1 DE60105025T DE60105025T DE60105025D1 DE 60105025 D1 DE60105025 D1 DE 60105025D1 DE 60105025 T DE60105025 T DE 60105025T DE 60105025 T DE60105025 T DE 60105025T DE 60105025 D1 DE60105025 D1 DE 60105025D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compounds
treating chronic
bronchopneumonia
obstructive
obstructive bronchopneumonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60105025T
Other languages
English (en)
Other versions
DE60105025T2 (de
Inventor
Kam-Wah Thong
Anthony J Kettle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60105025D1 publication Critical patent/DE60105025D1/de
Application granted granted Critical
Publication of DE60105025T2 publication Critical patent/DE60105025T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60105025T 2000-05-12 2001-05-08 Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie Expired - Fee Related DE60105025T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0011358 2000-05-12
GB0011358A GB2362101A (en) 2000-05-12 2000-05-12 Treatment of chronic obstructive pulmonary disease
PCT/SE2001/001014 WO2001085146A1 (en) 2000-05-12 2001-05-08 Pharmaceutical compounds for treating copd

Publications (2)

Publication Number Publication Date
DE60105025D1 true DE60105025D1 (de) 2004-09-23
DE60105025T2 DE60105025T2 (de) 2005-08-18

Family

ID=9891383

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105025T Expired - Fee Related DE60105025T2 (de) 2000-05-12 2001-05-08 Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie

Country Status (10)

Country Link
US (1) US20040029871A1 (de)
EP (1) EP1294366B1 (de)
JP (1) JP2004509841A (de)
CN (1) CN1427718A (de)
AT (1) ATE273699T1 (de)
AU (1) AU2001260880A1 (de)
CA (1) CA2406512A1 (de)
DE (1) DE60105025T2 (de)
GB (1) GB2362101A (de)
WO (1) WO2001085146A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3467101A (en) 2000-01-31 2001-08-07 Magainin Pharma Mucin synthesis inhibitors
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
SE0103766D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
MXPA03006549A (es) * 2003-07-22 2004-03-18 Univ Autonoma Metropolitana Uso de la dapsona como neuroprotector en el infarto cerebral.
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
SE0402591D0 (sv) * 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20110009351A1 (en) * 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
EP2247299A4 (de) * 2007-12-21 2012-06-06 Univ Rochester Molekulare targets zur behandlung von entzündungen
WO2011115778A2 (en) * 2010-03-15 2011-09-22 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
WO2011133581A1 (en) 2010-04-19 2011-10-27 General Atomics Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples
JP5976010B2 (ja) * 2010-12-23 2016-08-23 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Ｃｏｐｄを処置する方法
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
EP2682119A1 (de) * 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatische N-heterocyclische Derivate zur Verwendung als Medizin
MA42035A (fr) 2015-05-05 2018-03-14 Pfizer 2-thiopyrimidinones
AU2018304508B2 (en) * 2017-07-17 2021-06-10 Astrazeneca Ab MPO inhibitors for use in medicine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283564B6 (cs) * 1993-11-26 1998-05-13 Pfizer Inc. 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
WO1999059561A2 (en) * 1998-05-18 1999-11-25 Hensley, Kenneth, L. Resveratrol inhibition of myeloperoxidase
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.

Also Published As

Publication number Publication date
US20040029871A1 (en) 2004-02-12
WO2001085146A1 (en) 2001-11-15
CN1427718A (zh) 2003-07-02
EP1294366A1 (de) 2003-03-26
AU2001260880A1 (en) 2001-11-20
GB2362101A (en) 2001-11-14
GB0011358D0 (en) 2000-06-28
EP1294366B1 (de) 2004-08-18
ATE273699T1 (de) 2004-09-15
JP2004509841A (ja) 2004-04-02
DE60105025T2 (de) 2005-08-18
CA2406512A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60239554D1 (de) Medizinische vorrichtung zur abgabe von pflastern
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
SE0003476D0 (sv) Compounds
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
DE60130659D1 (de) Therapeutische verbindungen und verfahren
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
SE0004827D0 (sv) Therapeutic compounds
ATE322898T1 (de) Inhibitoren von mycobakterien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee